Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated March 1, 2022:
Effective March 1, 2022:
- Topical Doxepin
- Retinoids
- Enspryng
- Antidepressants
- ACA Prevention Copay Waiver
- Denosumab – Oncology
- Denosumab - Osteoporosis
- Emflaza
- Procysbi
- Progesterones
- Urea Cycle Disorders
Effective April 1, 2022:
- Colony Stimulating Factors
- Acute Migraine Agents
- Cholestasis Pruritus
- Amifampridine
- Oxybate
- Wakix
- VMAT2 Inhibitors
- CFTR
- Xhance
- Arikayce
- Corticotropin
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.
Institutional Providers
Professional Providers